(Q34083986)

30 July 2017

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein (English)

1 reference

30 July 2017

1 reference

4

1 reference

30 July 2017

J D Gillmore

1

1 reference

30 July 2017

L B Lovat

series ordinal

2

1 reference

30 July 2017

M R Persey

series ordinal

3

1 reference

30 July 2017

P N Hawkins

series ordinal

5

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

30 July 2017

1 reference

30 July 2017

358

1 reference

30 July 2017

24-29

1 reference

30 July 2017

9275

1 reference

A rapid method for measuring serum amyloid A protein by latex agglutination nephelometric immunoassay

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Treatment of amyloidosis and the rheumatologist. State of the art and perspectives for the future

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Behcet's disease and AA-type amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Complete clinical remission and subsequent relapse of bronchiectasis-related (AA) amyloid induced nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Clinical and therapeutic aspects of AA amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

A primed state exists in vivo following histological regression of amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905252-1

7 January 2021

10.1016/S0140-6736(00)05252-1

Identifiers

DOI

1 reference

30 July 2017

1 reference